Market Overview

Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches

Share:
Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches

Before Tuesday, 90 percent of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) analysts were buying the stock. But one analyst has diluted the decisive bullishness with rare ambivalence.

The Rating

Goldman Sachs analyst Dana Flanders initiated coverage on Alder with a Neutral rating and $17 price target.

The Thesis

The rating reflects ambiguity around commercial questions for IV eptinezumab, a calcitonin gene-related peptide monoclonal antibody inhibitor that Flanders said he expects to launch in the second half of 2019. (See the analyst's track record here.)

The analyst considers the significant and underserved migraine market a $5-billion opportunity, but also a highly competitive one. Amgen, Inc. (NASDAQ: AMGN), Eli Lilly And Co (NYSE: LLY) and Teva Pharmaceuticals Industries Ltd (ADR) ADR (NYSE: TEVA) are developing competing mAbs.

Goldman Sachs forecast five-year sales of around $650 million.

“We spoke with a neurologist at a leading academic headache center, who did not view current data supporting meaningful differentiation across CGRP agents,” Flanders said in a note. “However, she noted unmet need for new migraine therapies, was positive on overall CGRP efficacy and expected 25-percent to 33-percent uptake across eligible patients at her institution in four to five years.”

The estimates assume positive reimbursement conditions and the establishment of the long-term safety of the therapy. 

Price Action

Alder Pharma shares were down 2 percent at the time of publication Tuesday. 

Related Links:

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

The Size Effect Is Working With Health Care ETFs

Latest Ratings for ALDR

DateFirmActionFromTo
Sep 2019DowngradesBuyHold
Sep 2019ReiteratesNeutral
Sep 2019ReiteratesNeutral

View More Analyst Ratings for ALDR
View the Latest Analyst Ratings

Posted-In: Dana Flanders Goldman SachsAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (AMGN + ALDR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
UPSUBSMaintains136.0
TXNUBSMaintains110.0
SHWUBSMaintains570.0
PGUBSMaintains126.0
MCDUBSMaintains212.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Earnings Preview: Checking In On The Automakers With Reports From Ford And GM Coming Up

Upcoming Earnings: Twitter And Facebook Take The Stage On Wednesday